
https://www.science.org/content/blog-post/ancient-modeling
# Ancient Modeling
## April 2014

## 1. SUMMARY

The article reflects on a 1981 Fortune piece showing Merck scientists with primitive computer graphics of DNA, supposedly illustrating computer-aided drug design capabilities. The author notes the enormous gap between 1981 claims that scientists could "design drugs and check out their properties without leaving their consoles" and the 2014 reality where such capabilities still don't exist. The core argument is that computational power only helps when you already know how to calculate something accurately; it just does it faster. While 2014 had vastly improved processing power (smartphones, etc.), the fundamental challenge remained: molecular interactions—protein-DNA binding, water molecule behavior, entropy-enthalpy tradeoffs during binding events—were still poorly understood and difficult to model accurately. The accumulation of errors and uncertainties in modeling each step of biomolecular interactions meant that impressive graphics could mask fundamental gaps in scientific understanding, much like drawing a realistic-looking horse that might actually be filled with helium. The author suggests that overselling computational drug design capabilities has harmed the field by creating unrealistic expectations.

## 2. HISTORY

**2014-2020: Incremental progress in structural biology and computational methods**

After this article's publication, structural biology saw significant advances through cryo-electron microscopy (cryo-EM), which provided high-resolution protein structures that improved docking calculations. The Protein Data Bank continued expanding, giving modelers more reliable templates. Computational chemistry tools like Schrödinger's Glide, AutoDock, and GROMACS advanced significantly, better handling water molecules, electrostatics, and limited conformational sampling. However, drug discovery pipelines remained heavily experimental, with computational methods primarily used for early-stage screening and hypothesis generation rather than de novo drug design.

**Deep learning breakthrough (2016-2020)**
AlphaFold's release in 2018 (and particularly AlphaFold2 in 2020) revolutionized protein structure prediction, achieving accuracy comparable to experimental methods for many targets. This addressed part of the modeling challenge—knowing the protein structure—but not the full binding and dynamics problem the article highlighted.

**Industry reality check**
Major pharmaceutical companies continued investing in computational approaches but maintained hybrid experimental-computational workflows. Success stories emerged in specific areas: structure-based design contributed to kinase inhibitors (cancer drugs), HIV protease inhibitors, and some antivirals. However, the vision of "design drugs without leaving consoles" remained unrealized. Companies like Atomwise (founded 2012) pursued AI-based drug discovery, but most drug approvals still came through traditional discovery or computational-aided (not computational-driven) approaches.

**COVID-19 vaccine development (2020-2021)**
The rapid development of mRNA vaccines showcased computational biology's role in vaccine design, particularly in protein sequence optimization and structural modeling of the spike protein. However, this relied heavily on existing experimental platforms and massive parallel experimental validation.

## 3. PREDICTIONS

• **Implicit prediction: The gap between computational representation and biological reality will persist** ✓ **Mostly accurate**. While structural prediction improved dramatically with AlphaFold, predicting binding affinities, kinetics, and functional consequences purely computationally remains challenging. The 2024 state still requires extensive experimental validation.

• **Implicit expectation: Computational drug design would remain an assistive tool rather than replacement for experimental work** ✓ **Accurate**. As of 2024, AI and computational methods are valuable tools for screening, hypothesis generation, and optimization, but drug discovery pipelines remain experimental-heavy. No major drug class has been developed purely computationally without extensive experimental validation.

• **Implicit forecast: Better hardware alone wouldn't solve fundamental modeling limitations** ✓ **Accurate**. Despite exponential growth in computational power (GPU clusters, cloud computing), fundamental gaps in modeling solvent effects, entropy, and protein dynamics persist. Progress came from better algorithms and data (AlphaFold, cryo-EM structures), not just processing power.

## 4. INTEREST

Rating: **7/10**

This article stands out because it correctly identifies the central challenge: computational power alone can't overcome gaps in fundamental understanding of biomolecular physics. Written before AlphaFold, it anticipates why impressive graphics and processing speed don't automatically translate to predictive accuracy in drug design. Its insights remain relevant to current AI-in-drug-discovery discussions.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20140404-ancient-modeling.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_